Dogwood Therapeutics (NASDAQ:DWTX) Issues Earnings Results

Posted by Francis Steltz on Aug 15th, 2026

Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20), FiscalAI reports.

Dogwood Therapeutics Stock Performance

DWTX opened at $2.15 on Friday. Dogwood Therapeutics has a 52-week low of $1.28 and a 52-week high of $9.50. The firm has a market cap of $72.30 million, a P/E ratio of -0.24 and a beta of 1.71. The business’s fifty day moving average is $1.57 and its 200-day moving average is $2.04.

Institutional Investors Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. Institutional investors own 9.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on DWTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Friday, July 24th. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Dogwood Therapeutics in a research report on Tuesday, May 19th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.00.

Check Out Our Latest Stock Analysis on Dogwood Therapeutics

About Dogwood Therapeutics

(Get Free Report)

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.